Media stories about XOMA (NASDAQ:XOMA) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. XOMA earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.9994209728362 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several equities analysts recently weighed in on XOMA shares. Zacks Investment Research upgraded XOMA from a “hold” rating to a “strong-buy” rating and set a $33.00 price target for the company in a research note on Friday, November 10th. Wedbush upgraded XOMA from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $9.00 to $19.00 in a research note on Tuesday, September 5th. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of XOMA in a research note on Tuesday, November 7th. Finally, TheStreet upgraded XOMA from an “e+” rating to a “c-” rating in a research note on Wednesday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $30.00.

Shares of XOMA (NASDAQ:XOMA) traded up $0.41 during trading on Tuesday, hitting $32.29. The company had a trading volume of 143,900 shares, compared to its average volume of 153,446. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53. XOMA has a 1 year low of $3.96 and a 1 year high of $34.44.

In related news, CEO James R. Neal sold 11,568 shares of XOMA stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $30.83, for a total value of $356,641.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Thomas M. Burns sold 6,983 shares of XOMA stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $30.99, for a total value of $216,403.17. Following the completion of the sale, the chief financial officer now owns 13,538 shares in the company, valued at $419,542.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 87,069 shares of company stock valued at $2,517,993. 3.02% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “XOMA (XOMA) Earns News Sentiment Score of 0.16” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Insider Buying and Selling by Quarter for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with's FREE daily email newsletter.